EchoIQ Limited (AU:EIQ)
ASX:EIQ
Want to see AU:EIQ full AI Analyst Report?
Top Page
EchoIQ Limited
(Sydney:EIQ)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$1.50
â–²(23.97% Upside)
Action:Reiterated
Date:05/22/26
The score is held down primarily by weak financial performance (shrinking revenue, negative gross profit, large operating losses, and ongoing cash burn), partially offset by a strong technical uptrend and a low-debt balance sheet that reduces immediate financial distress risk. Valuation support is limited because earnings are negative and there is no dividend yield provided.
Positive Factors
Low leverage
Essentially no debt is a durable strength: it lowers solvency risk, reduces fixed interest obligations and preserves flexibility to raise or deploy capital during a multi-quarter restructuring or product pivot. This long-term optionality supports survival while management fixes fundamentals.
Negative Factors
Shrinking revenue
Sustained revenue decline reduces scale and undermines operating leverage, making it harder to absorb fixed costs and invest in growth. Over a multi-quarter horizon shrinking top line signals demand or execution issues that materially raise the risk of continued losses and funding needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Essentially no debt is a durable strength: it lowers solvency risk, reduces fixed interest obligations and preserves flexibility to raise or deploy capital during a multi-quarter restructuring or product pivot. This long-term optionality supports survival while management fixes fundamentals.
Read all positive factors
EchoIQ Limited (EIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$925.21M
Dividend YieldN/A
Average Volume (3M)2.50M
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth-30.02%
EPS Growth-54.94%
CountryAU
EmployeesN/A
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.02
Shares Outstanding660,862,730
10 Day Avg. Volume1,343,747
30 Day Avg. Volume2,496,323
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.66
Price to Sales (P/S)1270.57
P/FCF Ratio-19.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.40Price Target Upside15.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$1.10M
EchoIQ Limited Business Overview & Revenue Model
Company Description
Echo IQ Limited provides cardiac diagnostics support solution in Australia. The company offers artificial intelligence-assisted diagnostics technology that enhance the diagnosis of structural heart disease, as well as Aortic Stenosis. It primarily...
EchoIQ Limited Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.91K | 101.41K | 44.50K | 107.33K | 251.10K | 441.98K |
| Gross Profit | -9.09M | -3.14M | -2.88M | -7.01M | -3.19M | -1.75M |
| EBITDA | -15.58M | -12.74M | -4.81M | -7.66M | -5.85M | -3.14M |
| Net Income | -15.71M | -13.26M | -5.41M | -8.27M | -5.99M | -2.99M |
Balance Sheet | ||||||
| Total Assets | 17.99M | 23.37M | 8.26M | 10.38M | 10.23M | 10.93M |
| Cash, Cash Equivalents and Short-Term Investments | 11.21M | 6.62M | 2.12M | 3.28M | 2.41M | 3.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.83K |
| Total Liabilities | 718.61K | 615.41K | 1.49M | 3.00M | 2.21M | 1.10M |
| Stockholders Equity | 17.27M | 22.76M | 6.77M | 7.38M | 8.02M | 9.84M |
Cash Flow | ||||||
| Free Cash Flow | -8.34M | -6.54M | -3.92M | -5.28M | -2.95M | -2.43M |
| Operating Cash Flow | -8.28M | -6.51M | -3.92M | -4.94M | -2.58M | -1.43M |
| Investing Cash Flow | -2.06M | -11.55M | 0.00 | -59.81K | -367.33K | -1.00M |
| Financing Cash Flow | 16.21M | 22.56M | 2.77M | 5.88M | 1.55M | 2.77M |
EchoIQ Limited Technical Analysis
Positive
1.21
Price Trends
0.96
Positive
0.72
Positive
0.47
Positive
Market Momentum
0.08
Negative
71.68
Negative
98.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EIQ, the sentiment is Positive. The current price of 1.21 is above the 20-day moving average (MA) of 1.07, above the 50-day MA of 0.96, and above the 200-day MA of 0.47, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 71.68 is Negative, neither overbought nor oversold. The STOCH value of 98.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EIQ.
EchoIQ Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$101.31M | 15.19 | 11.24% | ― | 10.71% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
55 Neutral | AU$925.21M | -4.87 | -78.48% | ― | -30.02% | -54.94% | |
42 Neutral | AU$26.08M | -1.84 | -62.57% | ― | 36.04% | -71.94% | |
40 Underperform | AU$51.29M | -37.50 | -16.92% | ― | 11.52% | 41.43% | |
40 Underperform | AU$5.88M | -0.46 | 783.67% | ― | -13.82% | -132.50% |
* Technology Sector Average
AU:EIQ
EchoIQ Limited
1.40
1.13
409.09%
AU:UBN
Urbanise.com
0.65
-0.20
-23.53%
AU:HPG
hipages Group Holdings Ltd.
0.74
-0.13
-14.94%
AU:AR9
archTIS Ltd.
0.05
-0.01
-19.40%
AU:PRO
Prophecy International Holdings Ltd
0.07
-0.36
-83.02%
EchoIQ Limited Corporate Events
Echo IQ flags U.S. growth push with Mayo Clinic and Mount Sinai deals ahead of investor webinar
May 7, 2026
Echo IQ will host an investor webinar on 14 May 2026 to brief shareholders on strong U.S. commercial traction, including an expanded EchoSolv HF agreement with the Mayo Clinic that could open distribution across its platform network and more than ...
Echo IQ Accelerates U.S. Rollout as EchoSolv Usage Surges and Mayo, Mount Sinai Deals Advance
Apr 29, 2026
Echo IQ reported strong U.S. commercial momentum in the March quarter, highlighted by a distribution agreement with Mayo Clinic for EchoSolv HF once cleared, deployment of EchoSolv AS at New York’s Mount Sinai Health System, and a pipeline o...
Echo IQ deploys AI aortic stenosis tool at top-ranked Mount Sinai Health System
Apr 27, 2026
Echo IQ has deployed its EchoSolv AS decision support software for severe aortic stenosis into New York’s Mount Sinai Health System, which includes seven hospitals, more than 400 outpatient practices and a top-ranked cardiovascular program. ...
EchoIQ Director Increases Indirect Shareholding via Performance Rights Conversion
Apr 10, 2026
EchoIQ Limited has disclosed a change in director Steve Formica’s indirect holdings, following the vesting and exercise of a tranche of performance rights linked to the company’s share price. Through related party investment entities, ...
Echo IQ Issues New Shares on Exercise of Performance Rights
Apr 10, 2026
Echo IQ Limited has issued 1,625,000 fully paid ordinary shares following the exercise of vested performance rights, expanding its quoted share capital on the Australian Securities Exchange. The company advised that the shares were issued without ...
EchoIQ seeks quotation for 1.63 million new ASX shares
Apr 10, 2026
EchoIQ Limited has applied to the ASX for quotation of 1,625,000 additional ordinary fully paid shares, with an issue date of April 9, 2026. The new securities arise from the exercise or conversion of existing options or other convertible instrume...
Echo IQ issues 1 million new shares through option exercise
Apr 8, 2026
Echo IQ Limited has issued 1,000,000 fully paid ordinary shares following the exercise of unlisted options priced at $0.35 and expiring in June 2028, with the new shares forming part of its existing class quoted on the ASX. The company confirmed t...
EchoIQ seeks ASX quotation for 1 million new ordinary shares
Apr 8, 2026
EchoIQ Limited has applied for quotation on the ASX of 1,000,000 new ordinary fully paid shares, with an issue date of 8 April 2026. The application under Appendix 2A indicates these securities result from the exercise or conversion of existing in...
Echo IQ Deepens Mayo Clinic Pact Ahead of Potential EchoSolv HF FDA Clearance
Mar 23, 2026
Echo IQ has expanded its agreement with Mayo Clinic’s non-profit Mayo Foundation to allow resale and distribution of its EchoSolv HF heart failure decision support software via the Mayo Clinic Platform – Solutions Studio, contingent on...
Echo IQ Issues New Shares Following Option and Performance Right Exercises
Mar 17, 2026
Echo IQ has expanded its quoted share capital on the ASX by issuing 1.2 million fully paid ordinary shares from the exercise of unlisted options and a further 1.625 million shares from the exercise of vested performance rights. The company confirm...
EchoIQ seeks ASX quotation for 1.2 million new ordinary shares
Mar 17, 2026
EchoIQ Limited has applied for quotation on the ASX of 1.2 million new ordinary fully paid shares, with an issue date of March 16, 2026, under its existing ticker EIQ. The newly quoted securities arise from the exercise or conversion of existing o...
EchoIQ Director Increases Stake After Performance Rights Vesting
Mar 13, 2026
EchoIQ Limited has reported a change in the interests of director Steve Formica, reflecting the conversion of performance rights into ordinary shares via related party entities Stevsand Investments Pty Ltd and Formica Investments Pty Ltd. Followin...
EchoIQ Seeks ASX Quotation for 1.63 Million New Shares
Mar 13, 2026
EchoIQ Limited has applied for quotation of 1,625,000 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of March 11, 2026. The additional securities arise from the exercise or conversion of existing options o...
EchoIQ Added to S&P/ASX All Ordinaries in March 2026 Rebalance
Mar 10, 2026
EchoIQ Limited has been added to the SP/ASX All Ordinaries Index as part of SP Dow Jones Indices’ March 2026 quarterly rebalance, effective before the market opens on March 23, 2026. The inclusion places EchoIQ alongside a broad group of eme...
Echo IQ lodges interim financial report for half-year 2025
Feb 26, 2026
Echo IQ Limited has released its consolidated interim financial report for the half-year ended 31 December 2025, providing stakeholders with updated financial information and corporate disclosures. The report includes details of the company’...
Echo IQ posts wider half-year loss as revenues fall and asset backing weakens
Feb 26, 2026
Echo IQ Limited reported a 10.4% year-on-year decline in revenue from ordinary activities to $90,909 for the half-year ended 31 December 2025, alongside a widened after-tax loss of $8.66 million, up 39.3% from the prior corresponding period. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.